1.45 -0.03 (-2.03%)
After hours: 4:35PM EDT
|Bid||1.45 x 1300|
|Ask||1.48 x 1000|
|Day's Range||1.38 - 2.04|
|52 Week Range||0.70 - 2.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...
MELBOURNE, Australia, July 16, 2018-- Genetic Technologies Limited, a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that ...
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will enable both companies to collaborate to develop a service platform using blockchain technology that will provide a marketplace for medical services and personalised health management, and will also facilitate data management and AI-based services to promote better patient outcomes.
Project Shivom to provide GTG access to a significant pool of data, particularly related to the Indian population. GTG, through access to the Indian population data to modify its risk assessment kits as well as to develop new Indian specific tests or products, including tests related to diabetes and other disease, based on opportunity and areas of need.
Beyond 30,000, that’s where the Dow Jones Industrial Average (DJIA) is headed, according to Gene Simmons, known by many rock n’ roll fans as the KISS Demon. As of the close of trading on Tuesday, the Dow was sitting around 24,360, down 1.5% on the year. Since 1985, the Dow has gone through good times and bad, but has risen overall by nearly 1,800%.
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.
TORONTO , March 20, 2018 /CNW/ - Dan Kriznic , Chairman, CEO, Founder & Director, alongside Gene Simmons , Co-Founder of KISS, and Chief Evangelist Officer, Invictus MD Strategies Corp. (GENE), joined ...
NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Helios and Matheson Analytics Inc (NASDAQ: HMNY ) ...
NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Shares of Tetraphase Pharma and Genetic Technologies both climbed higher on Wednesday. Despite any news to serve as a catalyst for the gains, shares of Genetic ...